Partial
Mostly Not Aligned
Patient Risk:
Medium
Summary
Some mechanistic and interaction concepts (CYP3A4 involvement, grapefruit juice/CYP3A4 inhibitor effect, myopathy/rhabdomyolysis and liver enzyme monitoring, cyclosporine dose limit) are broadly consistent with the provided label excerpts, but multiple specific quantitative claims, supplement/diet risk thresholds, timing/spacing advice, and interaction breadth/risk-group assertions are not supported by the supplied LIPITOR label text and therefore reduce alignment.
Category Scores
Accurate Statements
Lipitor (atorvastatin) lowers cholesterol by inhibiting HMG-CoA reductase in the liver.
Section 12.1 (Mechanism of Action): LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase.
CYP3A4 is the main liver enzyme metabolizing atorvastatin.
Partially supported by label excerpts noting CYP3A4 inhibition effects on atorvastatin concentrations (Sections 7.1 and 7.2). (Label text provided does not explicitly state 'main enzyme'.)
Raised atorvastatin blood levels increase the risk of statin side effects like muscle pain (myopathy).
Section 5.1: concomitant use of higher doses with certain drugs such as cyclosporine and strong CYP3A4 inhibitors increases risk of myopathy/rhabdomyolysis.
Raised atorvastatin blood levels increase the risk of liver enzyme elevation.
Section 5.2: statins associated with biochemical abnormalities of liver function; persistent elevations occurred; liver function testing recommended.
Raised atorvastatin blood levels increase the risk of rhabdomyolysis in severe cases.
Section 5.1: rare cases of rhabdomyolysis reported; increased risk with strong CYP3A4 inhibitors/certain drugs.
Adding grapefruit juice, another CYP3A4 inhibitor, increases risk when combined with quercetin and atorvastatin.
Section 7.2 (Grapefruit Juice): grapefruit juice can increase plasma concentrations of atorvastatin, especially with excessive consumption (>1.2 liters/day). (Label does not mention quercetin combination.)
Unsupported Statements
Quercetin inhibits CYP3A4.
No quercetin-specific statements are present in the supplied LIPITOR label excerpts.
Quercetin potentially raises blood levels of atorvastatin by inhibiting CYP3A4.
Quercetin-specific interaction is not supported by the supplied LIPITOR label excerpts.
Quercetin reduces atorvastatin clearance by up to 30-40% in human liver microsomes and animal models.
No quantitative quercetin pharmacokinetic effect data appear in the supplied label excerpts.
The Lipitor (atorvastatin) and quercetin interaction is rated as moderate by drug interaction databases.
No database rating information appears in the supplied LIPITOR label excerpts.
The interaction is associated with advice for monitoring or dose adjustments.
No quercetin-specific monitoring/dose adjustment advice is present in the supplied label excerpts.
High-dose quercetin supplements (500-1000 mg/day) have been linked in case reports with elevated statin levels.
No quercetin supplement/case report information appears in the supplied label excerpts.
Food sources of quercetin (50-100 mg/day from diet) pose lower risk than high-dose supplements.
No quercetin dietary vs supplement risk comparisons appear in the supplied LIPITOR label excerpts.
Avoiding high-dose quercetin supplements (>250 mg/day) without doctor approval is recommended.
No quercetin supplement threshold or recommendation appears in the supplied LIPITOR label excerpts.
Spacing quercetin intake 2-4 hours apart from Lipitor is recommended.
No quercetin timing/spacing guidance appears in the supplied LIPITOR label excerpts.
Unexplained muscle weakness, dark urine, or fatigue are symptoms to monitor for.
No symptom list for atorvastatin adverse muscle events appears in the supplied label excerpts.
CK levels may be checked if needed.
No CK monitoring guidance appears in the supplied label excerpts.
Quercetin affects other CYP3A4 substrates.
No quercetin-specific statement appears in the supplied label excerpts.
Quercetin has stronger interactions with simvastatin and lovastatin than with atorvastatin.
No quercetin/statin comparative interaction statements appear in the supplied label excerpts.
Quercetin interacts with cyclosporine.
No quercetin-specific statement appears in the supplied label excerpts; cyclosporine is discussed only as a concomitant drug for atorvastatin dose limits (Section 2.6, Section 5.1).
Quercetin interacts with tacrolimus.
No quercetin-specific statement appears in the supplied label excerpts.
Quercetin interacts with some blood pressure medications.
No quercetin-specific statement appears in the supplied label excerpts.
No major interactions with non-CYP3A4 statins like rosuvastatin (Crestor) are reported.
No rosuvastatin-specific interaction statements appear in the supplied label excerpts.
Highest risk groups for the interaction include elderly patients (slower metabolism).
The label excerpts provided state plasma concentrations are higher in elderly (Section 12.3), but do not link this to a 'quercetin interaction' risk group.
Highest risk groups for the interaction include patients with liver impairment.
The label excerpts provided discuss liver dysfunction monitoring and hepatic impairment effects on concentrations, but do not describe a quercetin-specific interaction risk group.
Highest risk groups for the interaction include polypharmacy.
No polypharmacy risk-group assertion appears in the supplied label excerpts.
Genetic CYP3A4 poor metabolizers have amplified effects.
No genetic metabolizer guidance appears in the supplied label excerpts.
Contradictions
Important Omissions
Cyclosporine-specific maximum atorvastatin dose when co-administered (10 mg once daily; and guidance to limit dose when necessary).
Importance:
Moderate
Label-based requirement for liver function tests prior to and at 12 weeks, and specific action threshold for persistent ALT/AST elevations (>3 times ULN).
Importance:
Moderate
Grapefruit juice label threshold emphasizes excessive consumption (>1.2 liters/day); the AI did not provide this label-specific threshold.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The response includes several unsupported, specific quercetin dosing/timing and symptom/monitoring suggestions that are not grounded in the provided LIPITOR label excerpts. While some general safety concepts (myopathy/rhabdomyolysis and liver enzyme abnormalities with increased atorvastatin exposure; grapefruit juice increasing concentrations) align with the label, the unsupported supplement-specific guidance could mislead monitoring or dosing decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Major portion of the response concerns quercetin-specific interaction magnitude, dosing thresholds, timing, symptom monitoring, and risk-group assertions that are not supported by the provided FDA-approved LIPITOR label excerpts.
Suggested Improvement
Limit statements to labeling-supported information (e.g., grapefruit juice can increase atorvastatin concentrations, strong CYP3A4 inhibitors increase risk of myopathy/rhabdomyolysis, liver function testing and thresholds) and remove quercetin-specific quantitative and supplement-specific recommendations unless directly supported by the provided label text.